Published Apr 02, 2026

This practical CMC guide explains how apparent solubility, true thermodynamic solubility, and supersaturation differ, and why that distinction matters for solid form selection, dissolution method design, and formulation strategy.

What Apparent Solubility Actually Measures

Apparent solubility is a measured under specific experimental conditions. In many cases, it reflects a transient, non-equilibrium state rather than the true thermodynamic limit of the system.

That distinction is important. A measured value may include contributions from supersaturation, formulation effects, or incomplete equilibration. As a result, the number itself does not always represent what the system can sustain over time.

Apparent solubility is not only condition-dependent, but also solid form–dependent. Different polymorphs, salts, co-crystals, or amorphous forms can exhibit distinct dissolution and supersaturation behavior under the same conditions.

In practice, this means a measured concentration reflects not only the molecule, but also the specific solid form present at the time of measurement—including any transformation that may occur during the experiment. Without confirming the solid phase, it becomes difficult to determine whether a higher concentration reflects intrinsic solubility, transient supersaturation, or a change in form.

Both apparent and thermodynamic solubility describe the same system, but they capture different states. When supersaturation is not recognized, apparent solubility can be misinterpreted as an intrinsic property. When it is part of a formulation strategy, it must be evaluated in terms of how it evolves over time—how quickly it develops, how long it persists, and how rapidly it collapses. A single-point measurement cannot capture that behavior.

Why This Creates Risk in Dissolution Testing

Dissolution testing is often where misinterpreted solubility data has the greatest impact.

When a dissolution method is calibrated to an apparent solubility value—particularly when defining sink conditions—it may be based on a concentration that cannot be sustained under physiological conditions. In the gastrointestinal tract, pH transitions and fluid dynamics limit the persistence of supersaturation, which is often followed by precipitation. A method built on an inflated solubility value may show acceptable release profiles in vitro while failing to predict in vivo performance.

This risk is well illustrated by weakly basic BCS class IIb compounds such as ketoconazole. These compounds may dissolve readily in the acidic gastric environment, then supersaturate and precipitate as they transition into the higher pH of the intestine. [1] Conventional single-compartment dissolution methods—particularly those operating at a fixed pH—do not adequately capture this transition and may therefore overestimate performance. [2]

The same challenge applies to enabling formulations. Systems such as amorphous dispersions, co-crystals, and certain salts are designed to generate and maintain supersaturation in vivo. However, single-point solubility measurements cannot distinguish between a form that sustains concentration over time and one that peaks briefly and rapidly precipitates.

What differentiates effective formulations is not simply how high the concentration rises, but how long it remains within the absorption window. A formulation that cannot maintain supersaturation long enough for meaningful absorption has limited practical value, regardless of its apparent solubility. When decisions are based on single-point measurements alone, misranking can occur—often only becoming apparent later in dissolution testing or in vivo studies.

What Better Measurement Practice Looks Like

Improving solubility measurement does not require replacing standard assays. It requires understanding what each measurement represents and where it should be applied in development.

Thermodynamic solubility serves as the most reliable reference point. When measured at true equilibrium with confirmation of the solid phase, it defines the baseline behavior of a specific solid form in a given medium. This distinction is important, as different forms of the same compound can exhibit meaningfully different equilibrium solubility and transformation pathways. Establishing this baseline allows supersaturation behavior to be interpreted in the correct context and supports more reliable form selection.

Kinetic solubility serves a different purpose. It is valuable in early-stage screening, where speed and material efficiency are priorities. High-throughput methods such as nephelometry or UV-based assays can effectively rank compounds, but the results reflect metastable conditions and method-specific endpoints. These values are useful for prioritization, but they should not be directly translated into formulation design decisions or dissolution method development.

Supersaturation profiling tracks dissolved concentration over time after a controlled induction event. This is what enables meaningful evaluation of enabling formulations because it captures onset, duration, and collapse. For BCS class IIb compounds like ketoconazole, this time-dependent behavior is the relevant variable, and physiologically based multi-compartment dissolution approaches that simulate the gastric-to-intestinal pH shift have shown stronger IVIVC than conventional single-compartment methods precisely because they capture it. [1] For amorphous solid dispersions, standard non-sink conditions can trigger premature precipitation and underestimate performance, another case where time-based profiling gives a more accurate picture than a single endpoint. [3]

Solid Form as a Hidden Variable

Solid form is often the underlying driver of solubility variability. Differences in crystallinity, polymorphic form, or salt selection can influence not only equilibrium solubility, but also the ability to generate and sustain supersaturation.

In development, solubility should not be evaluated in isolation. It should be considered alongside solid form stability, transformation risk, and behavior under physiologically relevant conditions. Without this context, apparent differences in solubility may lead to incorrect form ranking and suboptimal formulation strategies.

For amorphous solid dispersions, this distinction is particularly important. Their performance depends not only on achieving supersaturation, but on maintaining it. Methods that rely on a single endpoint or poorly controlled conditions can underestimate formulation potential. In contrast, time-based profiling provides a clearer view of precipitation behavior and formulation robustness.

The Development Implication

Solubility is not a single number. It depends on solid form, measurement conditions, time, and the distinction between what a compound can transiently achieve and what it can sustain at equilibrium.

When this distinction is not clearly understood, the impact extends beyond early characterization. It propagates into dissolution method design, IVIVC modeling, and formulation selection. The challenge is not the lack of data, but the interpretation of that data in the correct context.

How Crystal Pharmatech Can Help

• For programs where solubility interpretation and dissolution performance present development risks, Crystal Pharmatech supports both the measurement and the decision-making behind it.

• Our capabilities integrate solid form understanding with solubility and formulation development, including thermodynamic solubility assessment with solid-phase control, supersaturation and precipitation profiling, and solid form screening and selection. We evaluate how different forms behave under development-relevant conditions to support informed form selection and reduce downstream risk.

• We also develop enabling formulations, including amorphous solid dispersions, supported by biorelevant dissolution testing to assess performance under physiologically relevant conditions.

• In addition, we apply physiologically based pharmacokinetic (PBPK) modeling to translate in vitro solubility and dissolution behavior into in vivo performance expectations. By connecting experimental data with mechanistic modeling, we help assess absorption risk, compare formulation strategies, and guide development decisions with greater confidence.

• The goal is not simply to generate more data, but to distinguish transient behavior from sustainable performance—and to ensure that solid form, formulation, and in vivo outcomes are aligned early in development.

References

1. 1. Gan Y, et al. Revisiting Supersaturation of a Biopharmaceutical Classification System IIB Drug: Evaluation via a Multi-Cup Dissolution Approach and Molecular Dynamic Simulation. Molecules. 2023;28(19):6962. https://doi.org/10.3390/molecules28196962

2. 2. Kostewicz ES, et al. Prediction of Ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling. European Journal of Pharmaceutics and Biopharmaceutics. 2017;113:72–81. https://doi.org/10.1016/j.ejpb.2016.12.017

3. 3. Bauer B, et al. Untangling "dissolved" drug species from various formulations of a poorly soluble drug: Sampling methods, mechanistic insights, and IVIVC. Journal of Pharmaceutical Sciences. 2025. https://doi.org/10.1016/j.xphs.2025.103756